Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma.
-
Authors
-
-
Santoni, Matteo1
-
Heng, Daniel Y C2
-
Aurilio, Gaetano3
-
Iozzelli, Andrea4
-
Servi, Lucilla5
-
Fabiani, Andrea5
-
Giannini, Massimo6
-
Mazzucchelli, Roberta7
-
Cimadamore, Alessia7
-
Scarpelli, Marina7
-
Zaghloul, Mohamed S8
-
Battelli, Nicola1
-
Montironi, Rodolfo7
-
1
Oncology Unit, Macerata Hospital, via Santa Lucia 2, Macerata, Italy.
,
(Italy)
-
2
Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.
,
(Canada)
-
3
IEO, European Institute of Oncology IRCCS, Medical Division of Urogenital and Head & Neck Cancer, Milan, Italy.
,
(Italy)
-
4
Radiology Unit, Macerata Hospital, via Santa Lucia 2, Macerata, Italy.
,
(Italy)
-
5
Urology Unit, Macerata Hospital, Via Santa Lucia 2, Macerata, Italy.
,
(Italy)
-
6
UOC Radioterapia Oncologica, Macerata Hospital, via Santa Lucia 2, Macerata, Italy.
,
(Italy)
-
7
Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.
,
(Italy)
-
8
Radiotherapy Department, National Cancer Institute, Cairo University & Children's Cancer Hospital Egypt (CCHE), Cairo, Egypt.
,
(Egypt)
- Type
- Published Article
- Journal
-
Current drug targets
- Publication Date
-
Jan 01, 2020
- Volume
-
21
- Issue
-
4
- Pages
-
416–423
- Identifiers
-
DOI: 10.2174/1389450120666191017113051
-
PMID: 31625471
- Source
-
Medline
- Keywords
-
- Language
-
English
- License
-
Unknown
Abstract
Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART cells in RCC. Copyright© Bentham Science Publishers; For any queries, please email at [email protected]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/23/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/31625471
